Evidence map›Paper›PMID 38292979›Full record

ReviewCureus2023

Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health.

Danish Saeed, Taufiqa Reza, Muhammad Waqas Shahzad, Alishba Karim Mandokhail, Danyal Bakht, Farwa Haider Qizilbash, Elizabeth O Silloca-Cabana, Afif Ramadhan, Syed Faqeer Hussain Bokhari

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Heat-KilledJournal of microbiology and biotechnology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. The Hidden Link between Chronic Kidney Disease and Lung Injury.American journal of respiratory cell and molecular biology · 2024
    Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Danish SaeedInternal Medicine, Shaikh Zayed Medical Complex, Lahore, PAK.
Taufiqa RezaInternal Medicine, Avalon University School of Medicine, Youngstown, USA.
Muhammad Waqas ShahzadGeneral Practice, Gujranwala Medical College, Gujranwala, PAK.
Alishba Karim MandokhailRadiology, Quetta Institute of Medical Sciences, Quetta, PAK.
Danyal BakhtMedicine and Surgery, Mayo Hospital, Lahore, PAK.
Farwa Haider QizilbashInternal Medicine, Dow Medical College, Karachi, PAK.
Elizabeth O Silloca-CabanaInternal Medicine, Wyckoff Heights Medical Center, Brooklyn, USA.
Afif RamadhanGeneral Practice, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Yogyakarta, IDN.
Syed Faqeer Hussain BokhariSurgery, King Edward Medical University, Lahore, PAK.
Mayo Hospital · PKUniversitas Gadjah Mada · IDGIFT University · PKShaikh Zayed Hospital · PKShaikh Zayed Postgraduate Medical Institute · PKWyckoff Heights Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Kidney Disease (CKD) has emerged as a global healthcare challenge affecting a significant portion of the world's population. This comprehensive narrative review delves into the intricate relationship between CKD and cardiovascular disease (CVD). CKD is characterized by kidney damage persisting for at least three months, often with or without a decline in glomerular filtration rate (GFR). It is closely linked with CVD, as individuals with CKD face a high risk of cardiovascular events, making cardiovascular-associated mortality a significant concern in advanced CKD stages. The review emphasizes the importance of precise risk assessment using biomarkers, advanced imaging, and tailored medication strategies to mitigate cardiovascular risks in CKD patients. Lifestyle modifications, early intervention, and patient-centered care are crucial in managing both conditions. Challenges in awareness and recognition of CKD and the need for comprehensive interdisciplinary care are highlighted. Recent advances in research offer promising therapies, such as SGLT2 inhibitors, MRAs, GLP-1R agonists, and selective endothelin receptor antagonists. Stem cell-based therapies, gene editing, and regenerative approaches are under investigation. Patient-physician "risk discussions" and tailored risk assessments are essential for improving patient outcomes. In conclusion, the review underscores the complexity of the interconnected CKD and cardiovascular health domains. Ongoing research, innovative therapies, and personalized healthcare will be instrumental in addressing the challenges, reducing the disease burden, and enhancing well-being for individuals facing CKD and cardiovascular issues. Recognizing the intricate connections between these conditions is imperative for healthcare providers, policymakers, and researchers as they seek to improve the quality of care and outcomes for affected individuals.

Indexed as

cardiovascular diseasecardiovascular eventschronic kidney diseaseckdcvdgfrglomerular filtration ratekidney damagemortalityrisk assessment

Identifiers

PMID38292979
PMCPMC10825078
OpenAlexW4390470365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.